202 related articles for article (PubMed ID: 24691192)
1. [Cancer-associated venous thromboembolic recurrence: disregard of treatment recommendations].
Mahé I; Chidiac J
Bull Cancer; 2014 Mar; 101(3):295-301. PubMed ID: 24691192
[TBL] [Abstract][Full Text] [Related]
2. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.
Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I
Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949
[TBL] [Abstract][Full Text] [Related]
3. Role of palliative low-molecular-weight heparin for treating venous thromboembolism in patients with advanced cancer.
Tran QN
Am J Hosp Palliat Care; 2010 Sep; 27(6):416-9. PubMed ID: 20197558
[TBL] [Abstract][Full Text] [Related]
4. The treatment of venous thromboembolism in patients with cancer.
Prandoni P
Intern Emerg Med; 2010 Oct; 5 Suppl 1():S27-30. PubMed ID: 20865471
[TBL] [Abstract][Full Text] [Related]
5. Treatment of venous thromboembolism in cancer patients.
Petralia GA; Kakkar AK
Semin Thromb Hemost; 2007 Oct; 33(7):707-11. PubMed ID: 18000799
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment of venous thromboembolism with tinzaparin compared to vitamin K antagonists: a meta-analysis of 5 randomized trials in non-cancer and cancer patients.
Laporte S; Bertoletti L; Romera A; Mismetti P; Pérez de Llano LA; Meyer G
Thromb Res; 2012 Dec; 130(6):853-8. PubMed ID: 22939430
[TBL] [Abstract][Full Text] [Related]
7. Lessons from French National Guidelines on the treatment of venous thrombosis and central venous catheter thrombosis in cancer patients.
Farge D; Durant C; Villiers S; Long A; Mahr A; Marty M; Debourdeau P;
Thromb Res; 2010 Apr; 125 Suppl 2():S108-16. PubMed ID: 20433988
[TBL] [Abstract][Full Text] [Related]
8. LMWH in cancer patients with renal impairment - better than warfarin?
Bauersachs RM
Thromb Res; 2016 Apr; 140 Suppl 1():S160-4. PubMed ID: 27067971
[TBL] [Abstract][Full Text] [Related]
9. Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study.
Kahn SR; Springmann V; Schulman S; Martineau J; Stewart JA; Komari N; McLeod A; Strulovitch C; Blostein M; Faucher JP; Gamble G; Gordon W; Kagoma PK; Miron MJ; Laverdière D; Game M; Mills A
Thromb Haemost; 2012 Sep; 108(3):493-8. PubMed ID: 22782073
[TBL] [Abstract][Full Text] [Related]
10. Venous thromboembolism in patients with advanced cancer under palliative care: additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practice.
Soto-Cárdenas MJ; Pelayo-García G; Rodríguez-Camacho A; Segura-Fernández E; Mogollo-Galván A; Giron-Gonzalez JA
Palliat Med; 2008 Dec; 22(8):965-8. PubMed ID: 18952751
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials.
Louzada ML; Majeed H; Wells PS
Thromb Res; 2009 Apr; 123(6):837-44. PubMed ID: 18977517
[TBL] [Abstract][Full Text] [Related]
12. Low molecular weight heparins in cancer. Management and prevention of venous thromboembolism in patients with malignancies.
ten Cate-Hoek AJ; Prins MH
Thromb Res; 2008; 122(5):584-98. PubMed ID: 17996281
[TBL] [Abstract][Full Text] [Related]
13. Guidelines for the management of cancer and thrombosis - Special aspects in women.
Bauersachs RM
Thromb Res; 2015 Feb; 135 Suppl 1():S16-22. PubMed ID: 25903527
[TBL] [Abstract][Full Text] [Related]
14. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism.
Louzada ML; Carrier M; Lazo-Langner A; Dao V; Kovacs MJ; Ramsay TO; Rodger MA; Zhang J; Lee AY; Meyer G; Wells PS
Circulation; 2012 Jul; 126(4):448-54. PubMed ID: 22679142
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulation therapy for prevention and treatment of venous thromboembolic events in cancer patients: a review of current guidelines.
Petersen LJ
Cancer Treat Rev; 2009 Dec; 35(8):754-64. PubMed ID: 19762155
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulant use in cancer patients.
Trujillo-Santos J; Monreal M
Expert Opin Pharmacother; 2011 Feb; 12(3):351-62. PubMed ID: 21254944
[TBL] [Abstract][Full Text] [Related]
17. Venous thromboembolism in patients with cancer: an overview for pharmacists using a case-based approach.
Pangilinan JM
J Pharm Pract; 2010 Aug; 23(4):294-302. PubMed ID: 21507829
[TBL] [Abstract][Full Text] [Related]
18. A review of the practical advantages of low molecular weight heparin in the treatment of cancer-related venous thromboembolism.
Rhodes S; Bond S
Eur J Oncol Nurs; 2008 Dec; 12(5):425-9. PubMed ID: 18842458
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment of deep-vein thrombosis with low-molecular-weight heparin: an update of the evidence.
Hull RD; Townshend G
Thromb Haemost; 2013 Jul; 110(1):14-22. PubMed ID: 23615656
[TBL] [Abstract][Full Text] [Related]
20. The NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease: strategies for improving VTE prophylaxis in hospitalized cancer patients.
Khorana AA
Oncologist; 2007 Nov; 12(11):1361-70. PubMed ID: 18055857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
